Reply to: Letter comments on: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers
- PMID: 34876300
- DOI: 10.1016/j.ejca.2021.10.038
Reply to: Letter comments on: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers
Conflict of interest statement
Conflict of interest statement DS has received research grants from Novartis, Bristol Myers Squibb, and Amgen; received consulting fees from, travel support from, and had advisory relationships with Novartis, Bristol Myers Squibb, MSD, Roche, Incyte, Array, Pierre Fabre, Pfizer, Sanofi-Genzyme, Regeneron, 4SC, InFlarX, Neracare, Ultimovacs, Sun Pharma, Philogen, Amgen, Merck-Serono, Immunocore, Sandoz-Hexal; received honoraria from Novartis, Bristol Myers Squibb, Pierre Fabre, Sanofi-Genzyme, and Merck-Serono; and held leadership or fiduciary roles with Dermatologic Cooperative Oncology Group (DeCOG), German Cancer Society, Hilfe-Stiftung, Deutsche Hautkrebsstiftung, NVKH eV, and EuMelaReg.
Comment on
-
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.Eur J Cancer. 2021 Aug;153:234-241. doi: 10.1016/j.ejca.2021.05.005. Epub 2021 Jul 2. Eur J Cancer. 2021. PMID: 34225229
-
Re: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.Eur J Cancer. 2022 Feb;162:241-242. doi: 10.1016/j.ejca.2021.10.037. Epub 2021 Dec 20. Eur J Cancer. 2022. PMID: 34949515 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials